Treatment of Stage I or II Oropharyngeal Cancer — Back of the Tongue, Soft Palate, or Tonsils (p16/HPV-Positive or p16/HPV-Negative)

Clinical Scenario

Early-stage oropharyngeal cancers arising in the back of the tongue, soft palate, or tonsils typically encompass most stage I and stage II presentations. This population includes both p16/HPV-positive and p16/HPV-negative tumors, which may inform risk stratification but share the same early-stage treatment framework.

Treatment Approach

Treatment at this stage centers on targeting both the primary tumor site and the regional lymph nodes in the neck. Management may involve a locoregional radiation strategy or a surgical approach to the primary tumor, with the status of the neck lymph nodes — as determined by imaging or biopsy — playing a key role in shaping the treatment path.

Full regimen details, clinical criteria, sequencing, and decision points are in the structured protocol below.

Instant Access to Structured Evidence-Based Regimens

References

Early-stage oropharyngeal cancers (back of the tongue, soft palate, and tonsils) typically include most stage I and II cancers, p16/HPV-positive or p16/HPV-negative.
Radiation therapy aimed at the cancer and lymph nodes in the neck, or surgery of the main tumor along with removal of the lymph nodes in the neck (lymph node dissection).
Sometimes, if imaging or a biopsy shows the lymph nodes in the neck have cancer, chemoradiation might be the first treatment.

View source ↗